TearSolutions, Inc. is a biotechnology company based in Charlottesville, Virginia, focused on developing innovative therapies for dry eye conditions. Founded in 2013, the company's primary product is Lacripep, a synthetic peptide derived from the natural tear protein lacritin, designed as a topical treatment for dry eyes. TearSolutions is currently advancing Lacripep through phase II human clinical trials, aiming to establish it as a novel replacement therapy. The company employs an outsourcing model to enhance its research and development efforts, reflecting its commitment to providing effective medical solutions for individuals suffering from dry eye syndrome.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.